Determining the Minimal Clinically Important Difference of the 40‐Item Smell Identification Test in People With Cystic Fibrosis
International Forum of Allergy & Rhinology · 2026
DOI: 10.1002/alr.70136 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Forum of Allergy & Rhinology, 2026. Verfasst von Eugene Oh und 34 weiteren Autor:innen. Beteiligte Einrichtung: University of California, Los Angeles, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Rhinosinusitis, Olfaction Disorders, Minimal Clinically Important Difference, Cystic Fibrosis. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIEHS NIH HHS, Cystic Fibrosis Foundation.
Abstract (Originalsprache)
Background
Chronic rhinosinusitis (CRS) and olfactory dysfunction (OD) are highly prevalent among people with cystic fibrosis (PwCF) and negatively impact quality of life. The 40‐item Smell Identification Test (SIT) is widely used to assess psychophysical olfaction, but a CF‐specific minimal clinically important difference (MCID) has not been established. This study aimed to determine the SIT MCID in PwCF treated with elexacaftor/tezacaftor/ivacaftor (ETI) and/or endoscopic sinus surgery (ESS).
Methods
Data from three prospective, multi‐institutional observational studies were pooled. Participants were ≥12 years old with confirmed CF and CRS who completed SIT at baseline and ≥1 follow‐up (3, 6, 9, 12, or 24 months). Distribution‐based MCIDs were calculated using four methods: standard error of measurement (SEM), minimal detectable change (MDC = 1.96 × SEM), 0.5 × baseline standard deviation (SD), and 0.5 × SD of change scores (ΔSD).
Results
A total of 122 participants were enrolled (mean age 32.9 years, 54% female). Of these, 99 contributed follow‐up SIT scores (79 ETI, 20 ESS). SIT scores remained stable with ETI, with a small but statistically significant decline at 6 months (−1.4, p = 0.02). ESS was associated with mean gains of 3.1–4.5 points at early follow‐up, though these did not reach significance. Pooled distribution‐based MCID estimates ranged from 2 to 4 points, with an overall threshold of 3.1 (95% CI: 2.1–4.1).
Conclusions
This CF‐specific SIT threshold provides a clinically interpretable cut‐off for assessing olfaction. These findings establish a foundation for future work and highlight the importance of developing disease‐specific MCIDs to guide clinical care and research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of California, Los Angeles, Los Angeles, California, USA.
- Department of Otolaryngology-Head and Neck Surgery, University of Michigan Health, Ann Arbor, Michigan, USA.
- Department of Head and Neck Surgery, University of California, Los Angeles, California, USA.
- Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Division of Biostatistics, National Jewish Health, Denver, Colorado, USA.
- Department of Otolaryngology-Head and Neck Surgery, University of Utah, Salt Lake City, Utah, USA.
ORCID-Profile: Eugene Oh, Anna Zemke, Jeremiah A Alt, David A Gudis, Peter H Hwang, Ashoke Khanwalkar, Jess C Mace, Jayakar V Nayak, Jonathan B Overdevest, Rodney J Schlosser, Brent Senior, Timothy L Smith, Daniel M Beswick
Förderung
- NIEHS NIH HHS
- Cystic Fibrosis Foundation
Zitieren
APA
Oh, E., Miller, J. E., Lee, M. J., Zemke, A., Baraghoshi, D., Strand, M. J., Alt, J. A., Bodner, T. E., Chang, M., Chowdhury, N. I., Eshaghian, P. H., Getz, A. E., Goralski, J. L., Gudis, D. A., Hwang, P. H., Khanwalkar, A., Kimple, A. J., Lee, J. T., Li, D. A., …, & Beswick, D. M. (2026). Determining the Minimal Clinically Important Difference of the 40‐Item Smell Identification Test in People With Cystic Fibrosis. International Forum of Allergy & Rhinology. https://doi.org/10.1002/alr.70136
Vancouver
Oh E, Miller JE, Lee MJ, Zemke A, Baraghoshi D, Strand MJ, et al. Determining the Minimal Clinically Important Difference of the 40‐Item Smell Identification Test in People With Cystic Fibrosis. International Forum of Allergy & Rhinology. 2026. doi:10.1002/alr.70136
BibTeX
@article{Oh2026,
author = {Oh, Eugene and Miller, Jessa E and Lee, Michelle J and Zemke, Anna and Baraghoshi, David and Strand, Matthew J and Alt, Jeremiah A and Bodner, Todd E and Chang, Michael and Chowdhury, Naweed I and Eshaghian, Patricia H and Getz, Anne E and Goralski, Jennifer L and Gudis, David A and Hwang, Peter H and Khanwalkar, Ashoke and Kimple, Adam J and Lee, Jivianne T and Li, Douglas A and Mace, Jess C and Nayak, Jayakar V and Overdevest, Jonathan B and Patel, Zara and Safatian, Daniella K and Schlosser, Rodney J and Senior, Brent and Stapleton, Amanda L and Smith, Timothy L and Soler, Zachary M and Suh, Jeffrey D and Turner, Grant A and Wang, Marilene B and Saavedra, Milene T and Taylor-Cousar, Jennifer L and Beswick, Daniel M},
title = {Determining the Minimal Clinically Important Difference of the 40‐Item Smell Identification Test in People With Cystic Fibrosis},
journal = {International Forum of Allergy & Rhinology},
year = {2026},
doi = {10.1002/alr.70136}
}
EUVIMED